FindTrial
Sign In

To assess response of tumor to chemotherapy given before surgery by using PET CT scan.

Prediction of tumor response to neo-adjuvant therapy in adenocarcinomas of the gastroeosphageal junction (AEG) using FDG PET/CT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2014/07/004767
Enrollment
75
Registered
2014-07-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients taking treatment of cancer

Interventions

None listed

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: All operated patients of esophageal adenocarcinoma who have undergone pre and post neo-adjuvant chemotherapy FDG PET/CT.

Exclusion criteria

Exclusion criteria: Previously operated patients Patients who have not undergone either the baseline or the post NACT PET/CT Patients who have received chemotherapy or radiation therapy prior to the initial PET/CT. Patients who are operated without receiving NACT.

Design outcomes

Primary

MeasureTime frame
Primary objective 1) To evaluate the ability of FDG PET/CT in predicting histopathological response after neo-adjuvant chemotherapy in patients with adenocarcinoma of the gastroesophageal junction. Timepoint: 2 years—

Secondary

MeasureTime frame
1.To assess if reduction in metabolism on FDG PET predict disease free survival (DFS) 2. To compare morphological response with histopathological response. Timepoint: 2 years—

Countries

India

Contacts

Public ContactDr Nilendu Purandare

Tata Memorial Hospital

nilpurandare@gmail.com9821468436

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026